A multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of ixmyelocel-T in subjects with critical limb ischemia and no options for revascularization.
Intramuscular injections of autologous Ixmyelocel-T cells versus placebo for the treatment of patients with peripheral artery disease and critical limb ischemia with no options for revascularization.
Age: >40 years. Duration: 12 months. Procedures: a bone marrow aspirate (removal of bone marrow from bone near the hip is performed) under moderate sedation is required for this study.
For more information, contact Schuyler Jones, MD at 919-681-3945.